Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351 | 0.86 | KDM1A (0.46) | HTTL3MBTL1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL29825639 | 0.86 | KDM1A (0.46) | HTTL3MBTL1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL29956372 | 0.83 | POLB (0.44) | L3MBTL1POLBALDH1A1TSHRLMNA | |
| SCHEMBL2802409 | 0.83 | POLB (0.44) | L3MBTL1POLBALDH1A1TSHRLMNA | |
| SCHEMBL14217725 | 0.81 | REN (0.38) | ENPP2 | |
| SCHEMBL13554245 | 0.80 | ENPP2 (0.33) | HTTLPLLIPGENPP2 | |
| SCHEMBL29427154 | 0.79 | ENPP2 (0.47) | HTTLMNAENPP2 | |
| SCHEMBL22471 | 0.79 | ENPP2 (0.47) | HTTLMNAENPP2 | |
| SCHEMBL11894322 | 0.79 | ALDH1A1 (0.41) | HTTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL3784737 | 0.79 | ALDH1A1 (0.59) | L3MBTL1POLBALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9376436-B2 | 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| EP-2794612-B1 | 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2015-08-13 | — | — | US | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-1856096-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1831217-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135993-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006069805-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | HTT 1352/4885L3MBTL1 2778/4885POLB 2436/4885 |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | SCN1A, SCN2A, SCN1B | HTT 1837/4885L3MBTL1 4624/4885POLB 4603/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | HTT 3772/4885L3MBTL1 2247/4885POLB 2996/4885 |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | TRPV1, TRPA1, TRPV5 | HTT 2233/4885L3MBTL1 4578/4885POLB 4819/4885 |
| US-10668067-B2 | Pyridine sulfonamides | TRPV1, TRPA1, TRPV5 | HTT 2233/4885L3MBTL1 4578/4885POLB 4819/4885 |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | HTT 2829/4885L3MBTL1 4173/4885POLB 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.